Name | [Pyr1]-Apelin-13 |
---|---|
Synonyms |
PGLU-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE
pQRPRLSHKGPMPF Deltorphin I PYR-RPRLSHKGPMPF-OH GLP-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE 5-Oxo-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-L-methionyl-L-prolyl-L-phenylalanine L-Phenylalanine, 5-oxo-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-leucyl-L-seryl-L-histidyl-L-lysylglycyl-L-prolyl-L-methionyl-L-prolyl- PYR-ARG-PRO-ARG-LEU-SER-HIS-LYS-GLY-PRO-MET-PRO-PHE pyroglutamyl apelin-13 |
Description | [Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist. |
---|---|
Related Catalog | |
In Vitro | [Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions[1]. |
In Vivo | [Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction[1]. [Pyr1] apelin-13 (1, 5 μg) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5 μg) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5 μg dose also produces significant attenuation in paw withdrawal threshold compared to SCI animals from the second week post SCI[2]. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Molecular Formula | C70H109N21O16S |
Molecular Weight | 1532.81 |
PSA | 613.26000 |
LogP | -3.42 |
Index of Refraction | 1.696 |
Storage condition | -15°C |
Detail
|
Literature: Zhang, Yanyan; Maitra, Rangan; Harris, Danni L.; Dhungana, Suraj; Snyder, Rodney; Runyon, Scott P. Bioorganic and Medicinal Chemistry, 2014 , vol. 22, # 11 p. 2992 - 2997 |
Precursor 7 | |
---|---|
DownStream 0 |